Innofluidics

Modern biotechnology processes - from biological drug manufacturing to industrial fermentation, from cell culture to advanced therapy development - depend on the ability to monitor in real time what is happening inside cells and bioreactors. But conventional analytical tools measure the culture medium, not what occurs inside the cell. Existing sensors detect parameters such as pH, dissolved oxygen, and temperature: useful information, but failing to capture the actual biology that determines process quality and yield. Innofluidics has identified this gap and is building the missing perception layer for what it calls Agentic Bioprocessing: the ability to obtain precise, real-time biological data from within the process, not just from the outside. The approach is that of advanced sensing applied to biological processes, with the goal of overcoming the limitations of existing sensors that sector users find increasingly insufficient. The application potential is broad. In pharmaceutical biologics production, real-time intracellular data can enable process condition optimisation and yield improvement, reducing the manufacturing costs of high-value therapies. In research, it enables better understanding of how cells respond to environmental changes. In new therapy development, it opens process control possibilities not currently available. The B2B2C model reflects a value chain in which Innofluidics provides the sensing technology integrated into bioreactor systems and process platforms, reaching end users through system partners. This is a deep tech bet in a high-impact sector, with significant technological barriers but a market that benefits directly from the innovation. Those who solve the problem of intracellular perception in a scalable and reliable way open a new class of possibilities for the whole of modern biotechnology.